Neumora Therapeutics, Inc.

Company Overview

Business Model: Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for brain and centrally mediated diseases. The company leverages a precision neuroscience approach, supported by its Precision Toolbox of translational neuroscience tools, methods, and data science capabilities, to identify and develop product candidates targeting novel mechanisms of action for underserved neuropsychiatric and neurodegenerative diseases, as well as metabolic disorders. Revenue generation is currently dependent on the successful clinical development, regulatory approval, and eventual commercialization of its product candidates.

Market Position: Neumora Therapeutics, Inc. operates in the highly competitive and rapidly changing biotechnology and biopharmaceutical industries, specifically targeting brain diseases, including neuropsychiatric disorders and neurodegenerative diseases, which have historically seen limited success in drug development. The company aims to differentiate itself through its precision neuroscience approach, integrating a portfolio of therapeutic candidates with novel mechanisms of action and advanced data science capabilities. Key programs are in development for Major Depressive Disorder (MDD), agitation associated with dementia due to Alzheimer’s disease (AD), schizophrenia, and obesity.

Recent Strategic Developments:

• Navacaprant (MDD): Initiated the KOASTAL pivotal Phase 3 program in 2023. Following the KOASTAL-1 study results in January 2025, which did not meet primary or key secondary endpoints, Neumora Therapeutics, Inc. conducted extensive analyses and made adjustments to the ongoing KOASTAL-2 and KOASTAL-3 studies. Topline data for KOASTAL-2 and KOASTAL-3 are expected in the second quarter of 2026.
• NMRA-511 (AD Agitation): Reported Phase 1b results in the first quarter of 2026, demonstrating a clinically meaningful effect size in patients with AD agitation, particularly in those with a Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) score ≥4. Multiple ascending dose (MAD) expansion cohort data is expected in the second half of 2026, with a Phase 2 study planned for the first quarter of 2027.
• NMRA-898 (Schizophrenia): Designated as the lead program in the M4 franchise in March 2026, based on promising Phase 1 single ascending dose (SAD) study results, including an approximately 80-100-hour half-life supporting once-daily dosing, dose-proportional exposures, and pharmacodynamic evidence of target engagement. MAD data is expected in the second half of 2026.
• NMRA-215 (Obesity): Announced preclinical weight loss data in October 2025, showing up to 19% weight loss as monotherapy and 26% in combination with semaglutide in diet-induced obesity (DIO) mouse studies. Clinical entry is now expected in the first quarter of 2027, following unexpected adverse findings in a 13-week rat toxicology study, which led to a for-cause audit and a repeat study.
• Financing: Entered into a loan and security agreement with K2 HealthVentures LLC in May 2025 for up to $125.0 million, with $60.0 million drawn as of December 31, 2025. Also continued an at-the-market (ATM) equity offering program, raising $19.7 million in net proceeds in 2025.

Geographic Footprint: Neumora Therapeutics, Inc.'s corporate headquarters are located in Watertown, Massachusetts, where it subleases approximately 10,000 square feet of office space. The company conducts preclinical research and clinical trials globally, with regulatory and commercialization efforts focused on the United States and other international markets.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no product revenue)
• Operating Margin: Not applicable (no product revenue)
• Net Margin: Not applicable (no product revenue)

Investment in Growth:

• R&D Expenditure: $176.1 million (73.0% of total operating expenses)
• Capital Expenditures: $82.9 million (purchases of marketable securities)
• Strategic Investments:
  • $5.0 million in acquired in-process research and development (Vanderbilt License Agreement milestone)
  • $6.3 million final payment to Amgen under the Amgen Collaboration Agreement
  • $1.5 million received from Parkinson’s Research Ventures Limited for NLRP3 program
  • $1.7 million received from The Michael J. Fox Foundation for Parkinson's Research for GCase program

Business Segment Analysis

Neumora Therapeutics, Inc. manages its business as a single operating segment focused on the development of clinical and preclinical neuroscience programs. The following breakdown reflects direct external program expenses within research and development.

Navacaprant (NMRA-140) Program

Financial Performance:

• Revenue: Not applicable (no product revenue)
• Direct External Program Expenses: $93.2 million (-11.6% YoY)
• Key Growth Drivers: Development for monotherapy treatment of Major Depressive Disorder (MDD). The KOASTAL pivotal Phase 3 program is ongoing, with topline data for KOASTAL-2 and KOASTAL-3 expected in Q2 2026.

Product Portfolio:

• Navacaprant (NMRA-140): A novel, oral once-daily, selective kappa opioid receptor (KOR) antagonist.

Market Dynamics:

• Targets over 21 million adults in the United States diagnosed with MDD, 85% of whom do not achieve remission with standard treatments. The KOR/dynorphin system represents a novel approach to treating MDD, anhedonia, and anxiety.

NMRA-511 Program

Financial Performance:

• Revenue: Not applicable (no product revenue)
• Direct External Program Expenses: $8.1 million (+11.9% YoY)
• Key Growth Drivers: Development for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD). Phase 1b results demonstrated a clinically meaningful effect size.

Product Portfolio:

• NMRA-511: A highly selective, novel antagonist of the vasopressin 1a receptor (V1aR).

Market Dynamics:

• The V1aR is implicated in aggression, affiliation, stress, and anxiety, suggesting therapeutic potential for agitation. New data from a pre-specified analysis of the Phase 1b study supports its clinical effect.

M4 PAM Programs (NMRA-898)

Financial Performance:

• Revenue: Not applicable (no product revenue)
• Direct External Program Expenses: $12.3 million (+11.2% YoY)
• Key Growth Drivers: Development for schizophrenia and other neuropsychiatric disorders. NMRA-898 designated as the lead program based on promising Phase 1 SAD study results, including a long half-life (80-100 hours) supporting once-daily dosing and evidence of target engagement.

Product Portfolio:

• NMRA-898 and NMRA-861: Highly potent and selective M4 muscarinic receptor positive allosteric modulators (PAMs). NMRA-898 is the lead program.

Market Dynamics:

• Aims to offer an improved therapeutic profile for schizophrenia over standard of care.

Preclinical Programs (NMRA-GCase, NMRA-CK1δ, NMRA-215)

Financial Performance:

• Revenue: Not applicable (no product revenue)
• Direct External Program Expenses: $11.0 million (+90.2% YoY)
• Key Growth Drivers: Advancement of programs for Parkinson’s Disease (NMRA-GCase), Amyotrophic Lateral Sclerosis (NMRA-CK1δ), and obesity (NMRA-215). Increased investment reflects ongoing preclinical research and manufacturing.

Product Portfolio:

• NMRA-GCase: An activator program for Parkinson’s Disease, focused on elevating glucocerebrosidase (GCase) activity.
• NMRA-CK1δ: A casein kinase 1 isoform delta (CK1δ) inhibitor program for Amyotrophic Lateral Sclerosis (ALS).
• NMRA-215: A highly brain-penetrant, oral NLRP3 inhibitor for obesity.

Market Dynamics:

• NMRA-GCase targets GBA1 gene mutations, a significant genetic risk factor for PD.
• NMRA-CK1δ targets TDP-43 phosphorylation, a key driver in most sporadic ALS cases.
• NMRA-215 targets NLRP3-mediated neuroinflammation in the hypothalamus to modulate appetite, showing class-leading weight loss in preclinical studies.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported for the years ended December 31, 2025 and 2024.
• Dividend Payments: Neumora Therapeutics, Inc. has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $182.5 million (as of December 31, 2025)
• Total Debt: $54.5 million (net of unamortized debt issuance costs and including accreted final payment fee, as of December 31, 2025)
• Net Cash Position: $128.0 million (Cash and cash equivalents + marketable securities - total debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The term loan facility with K2 HealthVentures LLC matures on May 1, 2029. Interest-only payments are required for the first 36 months (or 48 months if the second tranche is funded), followed by interest and principal payments for the next 12 months. Principal payments of $31.9 million are due in 2028 and $28.3 million in 2029 (including a $4.2 million final payment fee).

Cash Flow Generation:

• Operating Cash Flow: $(206.4) million (used in operating activities for 2025)
• Free Cash Flow: Not explicitly stated, but significant cash used in operating activities and for purchases of marketable securities.
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Neumora Therapeutics, Inc. does not own or operate any manufacturing facilities. It relies entirely on third-party contract manufacturing organizations (CMOs) for raw materials, drug substance, and drug product for its preclinical research and clinical trials. This reliance is expected to continue for later-stage development and commercialization. The company maintains internal personnel and third-party consultants to oversee these relationships.

Supply Chain Architecture: Neumora Therapeutics, Inc. depends on third-party CMOs for all manufacturing needs. Certain drug substance and drug product suppliers for navacaprant and NMRA-511 programs are single-source suppliers. These single-source agreements do not allow for termination for convenience, and there are no minimum purchase commitments.

Key Suppliers & Partners:

• Manufacturing Partners: Third-party CMOs for raw materials, drug substance, and drug product. Specific names are not disclosed, but some are noted as single-source suppliers for key programs (navacaprant, NMRA-511).
• Research Partners:
  • Amgen: Exclusive license agreements for CK1δ and GCase programs.
  • The Scripps Research Institute (TSRI): Exclusive license for navacaprant and NMRA-511 programs.
  • Vanderbilt University: Exclusive license for M4 PAM programs (NMRA-861, NMRA-898) and sponsored research agreements.
  • Parkinson’s Research Ventures Limited (PRV): Research funding agreement for NLRP3 program.
  • The Michael J. Fox Foundation for Parkinson's Research (MJFF): Research funding agreement for GCase program.

Facility Network:

• Corporate Headquarters: Watertown, Massachusetts (subleased office space of approximately 10,000 square feet).
• Manufacturing: Outsourced to third-party CMOs globally.
• Research & Development: Conducted internally and through collaborations with academic institutions and CROs.

Operational Metrics: No specific operational metrics such as capacity utilization or efficiency measures are disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Neumora Therapeutics, Inc. intends to retain significant development and commercial rights to its product candidates. If marketing approval is obtained, the company may commercialize its product candidates independently or with a partner in the United States and other geographies. The company currently lacks sales, marketing, or commercial product distribution capabilities and plans to build this infrastructure over time, leveraging technology for efficiency, or outsource these functions.

Distribution Channels:

• Direct Sales: Potential for an enterprise sales force and direct customer relationships if commercialization is pursued independently.
• Channel Partners: Potential for partnerships for marketing, sales, or distribution, especially in international markets.
• Digital Platforms: Potential for online sales channels and e-commerce initiatives, leveraging technology.

Customer Portfolio:

• Enterprise Customers: Not applicable at the current stage as no products are approved for commercial sale.
• Strategic Partnerships: Existing partnerships with Amgen, The Scripps Research Institute, and Vanderbilt University for intellectual property and research.
• Customer Concentration: Not applicable at the current stage.

Geographic Revenue Distribution: Not applicable as Neumora Therapeutics, Inc. has not generated any revenue from product sales.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and biopharmaceutical industries are highly competitive, characterized by rapid technological change, significant R&D investment, and a lengthy, expensive, and uncertain drug development process. The brain disease field, in particular, has historically seen limited success, making it a challenging area. Mergers and acquisitions among competitors further concentrate resources.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Neumora Therapeutics, Inc. competes with multiple biopharmaceutical and biotechnology companies, academic institutions, governmental agencies, consortiums, and public and private research institutions. Notable competitors in the brain disease space include:

• Axsome Therapeutics
• Denali Therapeutics
• Neurocrine Biosciences
• Prothena Corporation
• Xenon Pharmaceuticals

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in the rapidly evolving biotechnology and biopharmaceutical industries pose ongoing competitive threats. Advances in technologies and increased capital for investment in these industries could intensify competition.

Competitive Response Strategy: Neumora Therapeutics, Inc.'s strategy involves leveraging its precision neuroscience approach and a pipeline of therapeutic candidates with novel mechanisms of action to address the global brain disease crisis. This includes continued investment in internal discovery capabilities, business development activities to acquire and in-license assets, and enhancing its Precision Toolbox of translational neuroscience tools, methods, and data science capabilities.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company faces risks from the inherent difficulty and limited historical success in developing drugs for brain diseases, including neuropsychiatric and neurodegenerative disorders. Clinical or regulatory setbacks by Neumora Therapeutics, Inc. or competitors could negatively impact market perception and stock price. Technology Disruption: The company's precision neuroscience approach relies on third-party datasets and advanced machine learning capabilities. Failure to access additional datasets or enhance its approach could limit its strategy. Customer Concentration: Not applicable at the current stage as no products are approved for commercial sale.

Operational & Execution Risks

Supply Chain Vulnerabilities: Neumora Therapeutics, Inc. is entirely dependent on third-party CMOs for manufacturing, with some being single-source suppliers. Disruptions in supply, failure to comply with cGMP, or inability to secure alternative manufacturers could delay or impair development and commercialization. Supplier Dependency: Reliance on a limited number of suppliers for raw materials and single-source suppliers for drug products creates risk of supply interruptions, increased costs, or delays if suppliers face issues or prioritize other clients. Capacity Constraints: Not explicitly detailed, but reliance on third-party manufacturers implies potential exposure to their capacity limitations.

Financial & Regulatory Risks

Market & Financial Risks: The company has incurred significant losses since inception and expects to continue doing so, requiring substantial additional funding. Inability to raise capital on acceptable terms could force delays or elimination of development programs. Volatility in global credit and financial markets could exacerbate funding challenges. Regulatory & Compliance Risks: Drug development is subject to extensive, lengthy, and unpredictable regulation by the FDA and foreign authorities. Failure to obtain or maintain regulatory approvals, or comply with post-approval requirements (e.g., cGMP, GCPs, REMS), could severely harm the business. Changes in regulatory policies (e.g., EU Clinical Trials Regulation, UK legislation) could impact development plans and costs. Legal Proceedings: The company is currently subject to a putative class action lawsuit alleging Securities Act violations related to its initial public offering, which could result in substantial costs and diversion of management attention.

Geopolitical & External Risks

Geopolitical Exposure: Operating in international markets and relying on foreign CROs/CMOs exposes the company to geopolitical conflicts (e.g., Russia-Ukraine war, Middle East war), sanctions, and trade restrictions (e.g., U.S. BIOSECURE Act), which could increase costs, reduce supply, or limit market access. Trade Relations: Potential impact from trade tensions and policy changes affecting the pharmaceutical industry. Sanctions & Export Controls: Compliance with U.S. and foreign export/import controls, sanctions, and anti-corruption laws is required, with violations leading to substantial penalties.

Innovation & Technology Leadership

Research & Development Focus: Neumora Therapeutics, Inc. focuses its R&D on confronting brain diseases by developing novel therapies with brain-penetrant chemistry. Its approach integrates therapeutic candidates with novel mechanisms of action and a precision neuroscience approach, supported by its Precision Toolbox.

Core Technology Areas:

• Molecule Patents: Cover composition of matter and methods of treatment for product candidates.
• Precision Neuroscience Approach: Covers key artificial intelligence (AI) algorithms and machine learning (ML)-based processes for identifying and monitoring targeted patient populations.
• Biomarker Patents: Cover methods of diagnosing and treating patients using specific biomarkers.

Innovation Pipeline: The pipeline includes clinical-stage programs like navacaprant (MDD), NMRA-511 (AD agitation), and NMRA-898 (schizophrenia), as well as preclinical programs such as NMRA-GCase (Parkinson’s Disease), NMRA-CK1δ (ALS), and NMRA-215 (obesity). The company expects several program updates throughout 2026.

Intellectual Property Portfolio: As of December 31, 2025, Neumora Therapeutics, Inc. owns, co-owns, or exclusively licenses over 400 patents and pending applications in the U.S. and foreign jurisdictions, including 51 issued U.S. patents and 153 issued foreign patents.

• Navacaprant (NMRA-140): Covered by two patent families, including five issued U.S. patents, with expirations expected in 2033 and 2038 (excluding extensions). Licensed from The Scripps Research Institute (TSRI).
• NMRA-511: Covered by two issued U.S. patents and other applications, with expirations expected in 2038 (excluding extensions).
• M4R (NMRA-898, NMRA-861): Exclusively licensed from Vanderbilt University, including 19 issued U.S. patents, with expirations expected in 2044 (excluding extensions).
• Precision Toolbox: Covered by process patents and applications, including 18 issued U.S. patents, with expirations expected between 2038 and 2045 (excluding adjustments).
• Biomarker Patents: Over six patent applications relating to unimodal and multimodal biomarkers for patient identification and treatment.

Patent Strategy: The company's policy is to protect its proprietary position by filing U.S. and foreign patent applications for its technologies, inventions, and improvements. It also relies on trademarks, trade secrets, know-how, and continuous technological innovation.

Licensing Programs:

• Amgen Licenses: Exclusive licenses for CK1δ and GCase programs, with potential commercial milestone payments up to $360.0 million per product and tiered royalties.
• 2015 TSRI License Agreement: Exclusive license for KOR (navacaprant), V1aR (NMRA-511), and OTR programs, with potential development and regulatory milestones up to $1.5 million per program, commercial milestones up to $3.5 million per occurrence, and low-single digit royalties.
• Vanderbilt License Agreement: Exclusive license for M4 PAM programs, with potential development milestones up to $42.0 million (of which $7.0 million has been paid) and commercial milestones up to $380.0 million, plus mid-single digit tiered royalties.

IP Litigation: The company may be involved in lawsuits to protect or enforce its patents or those of its licensors, which can be expensive, time-consuming, and unsuccessful. It is also subject to claims of intellectual property infringement by third parties.

Technology Partnerships: Strategic alliances and research collaborations with academic institutions (e.g., The Scripps Research Institute, Vanderbilt University) and other organizations (e.g., Amgen, Parkinson’s Research Ventures Limited, The Michael J. Fox Foundation for Parkinson's Research) are integral to its R&D efforts.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success depends on attracting, hiring, and retaining key management and scientific personnel, particularly neuroscientists and data scientists, in a highly competitive talent market.

Board Composition: The board of directors is staggered into three classes serving three-year terms. Certain members were originally designated by principal stockholders (e.g., Amgen, ARCH Venture Partners). The Audit Committee oversees cybersecurity risks.

Human Capital Strategy

Workforce Composition: As of December 31, 2025, Neumora Therapeutics, Inc. had 96 full-time employees, with 56 primarily engaged in research and development activities.

Talent Management: Acquisition & Retention: The company's objectives include identifying, recruiting, retaining, incentivizing, and integrating employees. Equity incentive plans are used to attract, retain, and motivate personnel. Competition for qualified personnel in the biotechnology and biopharmaceutical industries is intense. Employee Value Proposition: Compensation philosophy, benefits, and culture are key to attracting and retaining highly skilled scientific, technical, and managerial employees.

Diversity & Development: No specific diversity metrics or development programs are disclosed in the filing.

Culture & Engagement: The company considers its relationship with employees to be good.

Environmental & Social Impact

No material information regarding specific environmental commitments, climate strategy, supply chain sustainability, or social impact initiatives is explicitly stated in the provided 10-K filing.

Business Cyclicality & Seasonality

Demand Patterns: Not applicable at the current stage as Neumora Therapeutics, Inc. has no commercial products and does not generate product revenue. Its operating results are subject to quarterly fluctuations primarily due to R&D expenses, clinical trial timing, and milestone payments. Economic Sensitivity: The company's business strategy and ability to raise additional funding may be adversely affected by economic downturns, volatile business environments, inflation, tariffs, trade controls, and interest rates. Industry Cycles: The biopharmaceutical industry is subject to lengthy and uncertain development cycles.

Planning & Forecasting: The company's future capital requirements depend on many factors, including the scope, timing, progress, and costs of its R&D programs and clinical trials.

Regulatory Environment & Compliance

Regulatory Framework: Neumora Therapeutics, Inc. is subject to extensive regulation by government authorities in the United States (FDA) and other countries regarding the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, and export/import of drug products. The EU Clinical Trials Regulation (CTR) and UK regulatory framework also apply to its clinical trials.

Industry-Specific Regulations:

• Drug Development & Approval: Requires preclinical studies (GLP), IND submissions, human clinical trials (GCPs), and New Drug Application (NDA) approval. The process is lengthy, expensive, and unpredictable.
• Post-Approval Requirements: Approved products are subject to ongoing regulation, including record-keeping, adverse event reporting, cGMP, and potential post-market studies or REMS.
• Off-Label Promotion: Strict regulations prohibit promotion of off-label uses, with potential for significant liability if violated.

Trade & Export Controls: The company is subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption laws (e.g., FCPA), and anti-money laundering laws. The U.S. BIOSECURE Act, enacted in December 2025, could restrict procurement from "biotechnology companies of concern," potentially impacting the company's foreign CROs and CMOs.

Legal Proceedings: As of February 6, 2025, Neumora Therapeutics, Inc. is a defendant in a putative class action lawsuit alleging violations of the Securities Act related to its initial public offering, claiming false and misleading statements in offering documents. The company believes these allegations lack merit and has moved to dismiss the amended complaint.

Tax Strategy & Considerations

Tax Profile: Neumora Therapeutics, Inc. has generated pre-tax net losses of $236.8 million in 2025 and $243.6 million in 2024, all from domestic operations. It accounts for income taxes under the asset and liability method, recognizing deferred tax assets and liabilities.

Effective Tax Rate: The effective income tax rate for 2025 was (0.1)% and for 2024 was (0.1)%. This is primarily due to a full valuation allowance against deferred tax assets, which offsets the income tax benefit at the statutory federal rate.

Geographic Tax Planning: The company files income tax returns in the United States and the states of California and Massachusetts.

Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, extended, modified, or made permanent many tax provisions from the Tax Cuts and Jobs Act of 2017, including immediate expensing of domestic R&D expenditures and modifications to business interest limitations. The company has reflected the effect of OBBBA in its 2025 financial statements.

Insurance & Risk Transfer

Risk Management Framework: Neumora Therapeutics, Inc. is exposed to potential product liability and professional indemnity risks inherent in biopharmaceutical product development and commercialization. It maintains product liability insurance for its product candidates and intends to expand coverage for commercial products if approved.

Insurance Coverage: The company maintains product liability insurance for its product candidates, but acknowledges that liabilities could exceed coverage. It also has directors' and officers' liability insurance. Risk Transfer Mechanisms: The company enters into agreements that may include indemnification provisions, particularly with directors and officers, and for losses arising from third-party actions. It also relies on contractual risk allocation with third-party manufacturers and CROs.